Is monitoring mean platelet volume necessary in breast cancer patients?

Taskaynatan H., ALACACIOĞLU A., KÜÇÜKZEYBEK Y., Varol U., Yildiz Y., Salman T., ...Daha Fazla

OPEN MEDICINE, cilt.13, sa.1, ss.450-455, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1515/med-2018-0067
  • Dergi Adı: OPEN MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.450-455
  • Anahtar Kelimeler: Breast cancer, Tamoxifen, Aromatase inhibitors, Mean platelet volume, Side effect, ADJUVANT ENDOCRINE THERAPY, CORONARY-ARTERY DISEASE, VENOUS THROMBOEMBOLISM, MYOCARDIAL-INFARCTION, AROMATASE INHIBITORS, ADVERSE EVENTS, RISK-FACTOR, TAMOXIFEN, ACTIVATION, METAANALYSIS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Mean platelet volume (MPV) is a parameter that increases during thrombotic and cardiovascular events. Tamoxifen (Tmx) and aromatase inhibitors (AIs), which are adjuvant endocrine therapies, may cause serious side effects, such as vascular thrombosis. The present study investigated the changes in MPV values of breast cancer patients receiving long-term adjuvant hormone therapy and the relationship of MPV with adverse effects of hormonotherapy.